Merck Serono Ventures sees Auxogyn license Stanford research.
Auxogyn, a US-based medical technology company, has licensed its first products since raising start-up funding in May.
Merck Serono Ventures, the corporate venturing division of Germany-based biotechnology company Merck, and venture capital firms Kleiner Perkins Caufield & Byers and TPG Biotechnology invested an undisclosed amount in Auxogyn to back the work of three Stanford University professors.
Auxogyn has now licensed the professors’ work to create its first products focused on helping women have babies through in vitro fertilization (IVF).
